230 related articles for article (PubMed ID: 26567178)
1. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study.
Saadoun D; Thibault V; Si Ahmed SN; Alric L; Mallet M; Guillaud C; Izzedine H; Plaisier A; Fontaine H; Costopoulos M; Le Garff-Tavernier M; Hezode C; Pol S; Musset L; Poynard T; Cacoub P
Ann Rheum Dis; 2016 Oct; 75(10):1777-82. PubMed ID: 26567178
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis.
Saadoun D; Pol S; Ferfar Y; Alric L; Hezode C; Si Ahmed SN; de Saint Martin L; Comarmond C; Bouyer AS; Musset L; Poynard T; Resche Rigon M; Cacoub P
Gastroenterology; 2017 Jul; 153(1):49-52.e5. PubMed ID: 28288791
[TBL] [Abstract][Full Text] [Related]
3. Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24.
Saadoun D; Resche Rigon M; Thibault V; Longuet M; Pol S; Blanc F; Pialoux G; Karras A; Bazin-Karra D; Cazorla C; Vittecoq D; Musset L; Decaux O; Ziza JM; Lambotte O; Cacoub P
Ann Rheum Dis; 2014 May; 73(5):831-7. PubMed ID: 23606708
[TBL] [Abstract][Full Text] [Related]
4. Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.
Comarmond C; Garrido M; Pol S; Desbois AC; Costopoulos M; Le Garff-Tavernier M; Si Ahmed SN; Alric L; Fontaine H; Bellier B; Maciejewski A; Rosenzwajg M; Klatzmann D; Musset L; Poynard T; Cacoub P; Saadoun D
Gastroenterology; 2017 Jun; 152(8):2052-2062.e2. PubMed ID: 28274850
[TBL] [Abstract][Full Text] [Related]
5. PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis.
Saadoun D; Resche Rigon M; Pol S; Thibault V; Blanc F; Pialoux G; Karras A; Bazin-Kara D; Cazorla C; Vittecoq D; Musset L; Peltier J; Decaux O; Ziza JM; Lambotte O; Cacoub P
J Hepatol; 2015 Jan; 62(1):24-30. PubMed ID: 25135864
[TBL] [Abstract][Full Text] [Related]
6. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Cacoub P; Saadoun D; Limal N; Sene D; Lidove O; Piette JC
Arthritis Rheum; 2005 Mar; 52(3):911-5. PubMed ID: 15751068
[TBL] [Abstract][Full Text] [Related]
7. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia.
Gragnani L; Visentini M; Fognani E; Urraro T; De Santis A; Petraccia L; Perez M; Ceccotti G; Colantuono S; Mitrevski M; Stasi C; Del Padre M; Monti M; Gianni E; Pulsoni A; Fiorilli M; Casato M; Zignego AL
Hepatology; 2016 Nov; 64(5):1473-1482. PubMed ID: 27483451
[TBL] [Abstract][Full Text] [Related]
8. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis.
Saadoun D; Resche-Rigon M; Sene D; Perard L; Karras A; Cacoub P
Ann Rheum Dis; 2008 Oct; 67(10):1431-6. PubMed ID: 18178690
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon- Alfa in Treatment of a Cohort of Egyptian Patients with Hepatitis C Virus Infection.
Ahmed OA; Kaisar HH; Hawash N; Samir H; Shabana SST; Hassan A Fouad M; Rizk F; Abd-Elsalam S
Infect Disord Drug Targets; 2017; 17(2):95-100. PubMed ID: 28413993
[TBL] [Abstract][Full Text] [Related]
10. Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia.
Calleja JL; Albillos A; Moreno-Otero R; Rossi I; Cacho G; Domper F; Yebra M; Escartín P
Aliment Pharmacol Ther; 1999 Sep; 13(9):1179-86. PubMed ID: 10468699
[TBL] [Abstract][Full Text] [Related]
11. Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study.
Saadoun D; Resche-Rigon M; Thibault V; Piette JC; Cacoub P
Arthritis Rheum; 2006 Nov; 54(11):3696-706. PubMed ID: 17075881
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study.
Mazzaro C; Dal Maso L; Quartuccio L; Ghersetti M; Lenzi M; Mauro E; Bond M; Casarin P; Gattei V; Crosato IM; De Vita S; Pozzato G
Clin Exp Rheumatol; 2018; 36 Suppl 111(2):107-114. PubMed ID: 29465371
[TBL] [Abstract][Full Text] [Related]
13. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study.
Mazzaro C; Zorat F; Caizzi M; Donada C; Di Gennaro G; Maso LD; Carniello G; Virgolini L; Tirelli U; Pozzato G
J Hepatol; 2005 May; 42(5):632-8. PubMed ID: 15826710
[TBL] [Abstract][Full Text] [Related]
14. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
[TBL] [Abstract][Full Text] [Related]
15. Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis.
Cacoub P; Si Ahmed SN; Ferfar Y; Pol S; Thabut D; Hezode C; Alric L; Comarmond C; Ragab G; Quartuccio L; Hegazy M; Poynard T; Resche Rigon M; Saadoun D
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):518-526. PubMed ID: 29857143
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
Younossi ZM; Stepanova M; Charlton M; Curry MP; O'Leary JG; Brown RS; Hunt S
Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):122-132. PubMed ID: 28404069
[TBL] [Abstract][Full Text] [Related]
17. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
Kowdley KV; Lawitz E; Crespo I; Hassanein T; Davis MN; DeMicco M; Bernstein DE; Afdhal N; Vierling JM; Gordon SC; Anderson JK; Hyland RH; Dvory-Sobol H; An D; Hindes RG; Albanis E; Symonds WT; Berrey MM; Nelson DR; Jacobson IM
Lancet; 2013 Jun; 381(9883):2100-7. PubMed ID: 23499440
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong.
Lai CL; Wong VW; Yuen MF; Yang JC; Knox SJ; Mo H; Han LL; Brainard DM; Chan HL
Aliment Pharmacol Ther; 2016 Jan; 43(1):96-101. PubMed ID: 26503414
[TBL] [Abstract][Full Text] [Related]
19. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.
Sise ME; Bloom AK; Wisocky J; Lin MV; Gustafson JL; Lundquist AL; Steele D; Thiim M; Williams WW; Hashemi N; Kim AY; Thadhani R; Chung RT
Hepatology; 2016 Feb; 63(2):408-17. PubMed ID: 26474537
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of sofosbuvir plus ribavirin in treatment-naive patients with genotype-1 and -3 HCV infection: results from a Russian Phase IIIb study.
Isakov V; Zhdanov K; Kersey K; Svarovskaia E; Massetto B; Zhu Y; Knox SJ; Bakulin I; Chulanov V
Antivir Ther; 2016; 21(8):671-678. PubMed ID: 27376706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
